Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reissued by research analysts at Cowen in a research note issued to investors on Tuesday. They presently have a $30.00 target price on the biopharmaceutical company’s stock. Cowen’s price target would suggest a potential upside of 169.78% from the stock’s current price.
Several other brokerages have also recently weighed in on DVAX. ValuEngine cut shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Royal Bank of Canada raised their price target on shares of Dynavax Technologies to $26.00 and gave the company an “outperform” rating in a research report on Monday, October 22nd. Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. BidaskClub cut shares of Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 18th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $28.25.
Shares of DVAX opened at $11.12 on Tuesday. Dynavax Technologies has a one year low of $9.63 and a one year high of $23.85. The stock has a market capitalization of $713.82 million, a PE ratio of -6.43 and a beta of 0.61. The company has a debt-to-equity ratio of 0.76, a current ratio of 8.87 and a quick ratio of 8.67.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The business had revenue of $1.46 million during the quarter, compared to the consensus estimate of $3.16 million. During the same period in the previous year, the business posted ($0.38) EPS. Dynavax Technologies’s revenue was up 2822.0% compared to the same quarter last year. On average, sell-side analysts forecast that Dynavax Technologies will post -2.39 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in shares of Dynavax Technologies by 5.2% during the 2nd quarter. BlackRock Inc. now owns 4,067,094 shares of the biopharmaceutical company’s stock worth $62,023,000 after buying an additional 202,306 shares in the last quarter. Senvest Management LLC lifted its position in shares of Dynavax Technologies by 52.7% during the 2nd quarter. Senvest Management LLC now owns 2,336,089 shares of the biopharmaceutical company’s stock worth $35,625,000 after buying an additional 806,102 shares in the last quarter. Eagle Asset Management Inc. bought a new position in shares of Dynavax Technologies during the 2nd quarter worth approximately $35,054,000. Chicago Capital LLC lifted its position in shares of Dynavax Technologies by 74.0% during the 3rd quarter. Chicago Capital LLC now owns 2,252,046 shares of the biopharmaceutical company’s stock worth $27,925,000 after buying an additional 957,942 shares in the last quarter. Finally, PointState Capital LP bought a new position in shares of Dynavax Technologies during the 2nd quarter worth approximately $28,800,000. 81.48% of the stock is currently owned by institutional investors and hedge funds.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Featured Article: Yield Curve
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.